Egypt - English - EDA (Egyptian Drug Authority)

waki pharma - ampicillin trihydrate 22.30 gm/100ml (eq.to ampicillin base 20 gm.) - water soluble powder

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - ampicillin trihydrate (unii: hxq6a1n7r6) (ampicillin - unii:7c782967rd) - ampicillin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.  when culture and susceptibility information are available, they should be considered in selecting of modifying anitimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: infections of the genitourinary tract including gonorrhea - e. coli, p. mirabilis , enterococci, shigella , s. typhosa and other salmonella and nonpenicillinase-producing n. gonorrhoeae . infections of the respiratory tract - nonpenicillinase-produc

United States - English - NLM (National Library of Medicine)

par pharmaceutical - ampicillin trihydrate (unii: hxq6a1n7r6) (ampicillin - unii:7c782967rd) - ampicillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.  when culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: infections of the genitourinary tract including gonorrhea - e. coli, p. mirabilis , enterococci, shigella, s. typhosa and other salmonella and nonpenicillinase-producing n. gonorrhoeae . infections of the respiratory tract - nonpenicillinase-producing

United States - English - NLM (National Library of Medicine)

hospira, inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin 1 g

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - ampicillin trihydrate (unii: hxq6a1n7r6) (ampicillin - unii:7c782967rd) - ampicillin 500 mg

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli* , klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis* , bacteroides fragilis* , enterobacter spp.*, and acinetobacter calcoaceticus*. note: for information on use in pediatric patients see precautions, pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli* , and bacteroides spp.* (including b. fragilis* ). * efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicilli

United States - English - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,* klebsiella spp.* (including k. pneumoniae *), proteus mirabilis ,* bacteroides fragilis ,* enterobacter spp.,* and acinetobacter calcoaceticus .* note: for information on use in pediatric patients (see precautions - pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae *), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli ,* and bacteroides spp.* (including b. fragilis *). * efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicillin and sulbactam for injection is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with ampicillin and sulbactam for injection due to its ampicillin content. therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to ampicillin and sulbactam for injection should not require the addition of another antibacterial. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to ampicillin and sulbactam for injection. therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. once the results are known, therapy should be adjusted if appropriate. to reduce the development of drug-resistant bacteria and maintain effectiveness of ampicillin and sulbactam for injection and other antibacterial drugs, ampicillin and sulbactam for injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. the use of ampicillin and sulbactam for injection is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or stevens-johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). ampicillin and sulbactam for injection is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with ampicillin and sulbactam for injection.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli * , klebsiella spp.* (including k. pneumoniae * ), proteus mirabilis * , bacteroides fragilis * , enterobacter spp.* , and acinetobacter calcoaceticus * . note: for information on use in pediatric patients see precautions-pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae * ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli * , and bacteroides spp.* (including b. fragilis * ). *efficacy for this organism in this organ system was studied in fewer than 10 infections. wh

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: respiratory tract infections  caused by streptococcus pneumoniae , staphylococcus aureus  (penicillinase and nonpenicillinase-producing), h. influenzae , and group a beta-hemolytic streptococci. bacterial meningitis  caused by e. coli , group b streptococci, and other gram-negative bacteria (listeria monocytogenes , n. meningitidis ). the addition of an aminoglycoside with ampicillin may increase its effectiveness against gram-negative bacteria. septicemia and endocarditis  caused by susceptible gram-positive organisms including streptococcus spp., penicillin g-susceptible staphylococci, and enterococci. gram-negative sepsis caused by e. coli , proteus mirabilis  and salmonella  spp. responds to ampicillin. endocarditis due to enterococcal strains usually respond to intravenous therapy. the addition of an aminoglycoside may enhance the

United States - English - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,* klebsiella spp .* (including k. pneumoniae*), proteus mirabilis ,* bacteroides fragilis ,* enterobacter spp. ,* and acinetobacter calcoaceticus .* note: for information on use in pediatric patients (see precautions-pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp . (including k. pneumoniae *), bacteroides spp . (including b. fragilis ), and enterobacter spp .* gynecological infections caused by beta-lactamase producing strains of escherichia coli ,* and bacteroides spp.* (including b. fragilis *). * efficacy for this organism in this organ system was studied in fewer than 10 infections. while a